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Carcinogenesis in Transgenic
Mouse Models
In the highly competitive world ofpharma-
ceutical sales, what could possibly bring
more than twenty pharmaceutical compa-
nies together to workcooperatively and share
resources and information? Apparently, the
work of the NIEHS Laboratory of
Environmental Carcinogenesis and
Mutagenesis (LECM) has done it. Many
U.S. pharmaceutical companies are collabo-
rating on the use of a transgenic mouse
bioassaydevelopedbythe LECM to identify
toxicand carcinogenic compounds.
Toxicity of pharmaceuticals, as well as
other compounds to which humans are
exposed, is currently identified using a
two-year bioassay for carcinogenesis devel-
oped bythe NTP. This bioassay, which has
become the scientific standard for animal
bioassays, uses B6C3F1 mice and Fischer
344/N rats ofboth sexes. In the traditional
bioassay, animals are dosed with a test
-chemical for 104 weeks and then analyzed
for neoplastic effects.
Transgenic mouse models developed by
the LECM are genetically altered so as to
be predisposed to develop tumors, but the
alteration is insufficient to actually cause
tumors on its own. The models overcome a
major shortcoming of traditional two-year
bioassays-the length of time they take to
perform. Mice have a life span ofapproxi-
mately 2-3 years; therefore, by the time
traditional bioassays are complete, the
mouse subjects are reaching the end of
their life span. As with all animals, the ten-
dency to develop tumors increases with the
age of the mice. "By having
a short-term carcinogenesis
assay, we can differentiate
between age-related carcino-
genesis and chemical car-
cinogenesis," said LECM
investigatorJohn E. French.
The LECM's transgenic
mouse bioassay could cut
the time for obtaining
results from traditional
bioassays from up to four
years to one year. This
could, in turn, cut the
amount oftime required for
approval of drugs by the
Food and Drug Admin-
istration, which requires
toxicity testing of drugs
before they can be sold to
the public, resulting in large
financial savings and poten-
tially hastening a product to
the market. Ray Tennant, Transgenic tea
chief of the LECM, said, (seatedl.tor.)Ra
"This effort by the pharmaceutical compa-
nies will provide a principle source ofdata
that will be used to develop the test proto-
col [for the bioassay] and to judge the
appropriate uses of the model. Because we
can pool resources and evaluations, it could
take as little as 1-2 years to know howwell
the transgenic model duplicates the two-
year bioassay."
Scientists in the LECM have already
shown a high concordance between results
of the transgenic models and the two-year
bioassay. For example, transgenic mice
lacking the p53 gene develop some of the
same types oftumors and in the same sites
as mice in the two-year bioassay, but they
develop tumors in 6 months instead of
1.5-2 years. The NTP is interested in eval-
uating the transgenic model for its own
purposes. "We are laying the foundation, I
think, for the transition to transgenics,"
said Tennant. "It is inevitable that we
switch to transgenics; we learn more, spend
less money, and in less time. How can you
beat that?"
TgAC Model
The LECM is currently working with two
transgenic models, the Tg.AC model and
the p53 model. The Tg.AC model was
developed by Philip Leder at Harvard
Medical School as a skin cancer model
with a reporter phenotype. It carries an
activated v-Ha-ras oncogene that alters sig-
nal transduction and growth control. The
second model used by LECM is the het-
erozygous p53-deficient mouse model,
which was developed by Larry Donehower
am. (standing 1. to r.) John E. French, Carol Trempus, Mik
iyTennantJudsonSpalding.(Notpictured) RonCannon,RandallFai
and Allan Bradley at Baylor College of
Medicine in Texas. This model is a strain
ofmice in which one ofthe two function-
ing p53 alleles has been "knocked out."
Thep53 gene is critical to a cell's response
to environmental stress, including cell
cycle control and DNArepair.
LECM researcher Judson Spalding is
studying carcinogenesis in the Tg.AC
transgenic model. Other investigators have
previously shown that mutation ofthe cel-
lular Ha-ras gene is an early event in the
development of skin tumors. "We have
truncated the multi-stage process by genet-
ically initiating this early event," said
Spalding. Initially, an evaluation ofchemi-
cal activity via topical application in the
Tg.AC model was begun by selecting
chemicals with known activity in the NTP
two-year bioassay. The chemicals were
selected to represent a broad spectrum of
genotoxic and nongenotoxic chemicals.
"The agreement of chemical activity with
the two-year bioassay results was high, at
88%," said Spalding. Since these studies
were completed, nearly 40 other chemicals
have been tested or are currently being
tested with the model by the NIEHS and
other researchers.
Spalding said, "We originally got into
this to look at chemical carcinogenesis but
we are now interested in understanding the
biology of skin tumor induction in these
mice in order to understand the early
events involved." Spalding is most interest-
ed in the wound response. When these ani-
mals are wounded, papillomas can arise in
the wound line within 4-5 weeks. "An
important feature of the
Tg.AC mice," he said, "is that,
with the exception ofthe bone
marrow, the transgene is not
constitutively expressed in the
skin or other tissues; converse-
ly, we have never seen either
spontaneous or induced
tumors at any target organ site
that did not express the trans-
gene." Therefore, the trans-
gene must be activated in the
wounding process. The ques-
tion is how.
One hypothesis, being
explored by Spalding in col-
laboration with NIEHS re-
searcher Robert Langenbach,
is that inflammation is an
important component of skin
tumor induction. Langenbach's
group is interested in the
effects of non-steroidal anti-
e Battalora. inflammatory drugs (NSAIDs)
ircloth. on the development ofcancer.
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Spalding and Langenbach are trying to
answer the question of whether NSAIDs
inhibit the development of papillomas by
inhibiting the clonal expansion of preneo-
plastic cells in the Tg.AC mice.
LECM researcher Ron Cannon is
responsible for investigating the molecular
biology of Tg.AC carcinogenesis. Cannon
is interested in determining the molecular
requirements for activating the Tg.AC
transgene. "What I want to answer," said
Cannon, "is why Tg.AC's transgene
responds specifically to carcinogens and
wounding." Tg.AC's transgene contains
the oncogene v-Ha-ras, which has been
integrated into the genome of the trans-
genic mice. The v-Ha-ras oncogene is
under the transcriptional control of a par-
tial zeta-globin promoter. The natural
zeta-globin gene encodes the embryonic
protein, which is normally expressed dur-
ing days 8-15 in the blood islands of the
yolk sac. This particular promoter requires
an enhancer-an additional region of
DNA located 40,000 base pairs upstream
of the promoter and the transgene. This
enhancer was not included in the Tg.AC
model's transgene construct. However, the
transgene is still expressed in the skin of
Tg.AC mice. Cannon suggests that the
transgene in the model has integrated near
a region that can substitute for the
required promoter control region of the
transgene.
Cannon has shown with a technique
called fluorescence in situ hybridization
that the transgene localizes at a single inte-
gration site on chromosome 11 near the
centromere. He has also shown that it inte-
grates in stable tandem arrays of4-6 copies
ofthe transgene. Cannon searched for tran-
scription factors known to regulate zeta-
globin transcription in other tissues and
then looked for those same factors in the
skin of the model mice. He found that
transcription factors in epithelial cells bind
a factor known to be required for zeta-glo-
bin expression, a member of the family of
zinc finger transcription factors called
GATA. Tennant's group had previously
shown by in situ hybridization that the
transgene is activated in the cells ofhair fol-
licles. Cannon has recently shown that
there is expression of GATA transcription
factors in a specific group ofcells associated
with the hair follicle. Taken together, this
implies there is a stem cell residing in the
hair follicle that is the target cell at risk for
tumorigenesis in Tg.AC transgenic mice.
p53Model
French is studying the p53 transgenic
mouse model. Current knowledge says that
Model mice. Transgenic mice models may one day replace traditional two-year mouse bioassays cur-
rently used to testfor carcinogenesis.
carcinogenic development is a multi-step
process-that it requires several genetic
events for cancer to develop. "The trans-
genic models corroborate the genetic role
of proto-oncogenes and tumor suppressor
genes," said French. In 1995, French and
his colleagues published their results
regarding the hemizygous p53 transgenic
model in the October issue ofEHP. In this
study, they looked at five chemicals: 4-
vinyl-1-cyclohexene diepoxide, p-cresidine,
p-anisidine, N-methylolacylamide, and
reserpine. In all cases, the transgenic model
reproduced the tumor induction seen by
the NTP bioassay in number and location.
"We showed reproducibility. I find that
very reassuring," said French.
When French removed the tumors that
developed in the transgenic mice to search
for the genetic event or lesion that caused a
tumor to develop, he expected to see loss
ofthe only functional p53 allele. Although
French did find such a loss in some cases,
he did not find it as often as he had antici-
pated. For example, when animals were
treated with p-cresidine, an aromatic
amine that causes bladder tumors, only
one-fifth of the tumors induced lost the
wild-type p53 allele. In animals treated
with the human carcinogen benzene,
French observed a loss of the p53 allele in
two-thirds ofthe tumors examined.
French's group also expected to find
mutations in the lone functional p53 allele
when they didn't see loss. Normally, when
mutations are found in the p53 gene, they
are most often found in exons 4, 5, 6, 7,
and 8. French used a technique called sin-
gle strand conformational polymorphism to
screen for mutations in p53 in bladder
tumors. "We seldom found mutation in
exons 4-8 ofp53 in the bladder tumors,"
said French, "yet we can observe mutation
in the bacterial lac neutral reporter gene,
which demonstrates mutagenization of the
bladder and indicates that other critical
genes can be mutated." In contrast, in ani-
mals treated with phenolphthalein, a chem-
ical recently eliminated from laxative for-
mulations by drug manufacturers due to its
carcinogenic potential, every tumor lost the
whole p53 wild-type allele. "These studies
suggest that this model may be appropriate
for identifying mutagenic carcinogens inde-
pendent of mutations or loss of the p53
wild-type allele," said French. "Now we
have a dichotomy. There aren't many genes
that are critical in cells ofall types, butp53
is involved in . . . up to 80% of cancers.
Thep53-deficient mouse is set up for chro-
mosomal, genetic, and other critical events
that drive tumorigenicity."
The p53 gene sits at the junction of
many pathways, including cell cycle events,
DNA replication, and apoptosis (or pro-
grammed cell death). All ofthese processes
are important to tumorigenesis and are
currently being researched by scientists all
over the world. The Tg.AC and the p53
transgenic models developed by the LECM
may offer such scientists a faster, cheaper,
and easier way to answer many basic ques-
tions about tumorigenicity.
TracyLyon
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